Z-Asp-CH2-DCB structure
|
Common Name | Z-Asp-CH2-DCB | ||
---|---|---|---|---|
CAS Number | 153088-73-4 | Molecular Weight | 454.258 | |
Density | 1.4±0.1 g/cm3 | Boiling Point | 674.2±55.0 °C at 760 mmHg | |
Molecular Formula | C20H17Cl2NO7 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 361.6±31.5 °C |
Use of Z-Asp-CH2-DCBZ-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development[1][2][3]. |
Name | z-asp-2,6-dichlorobenzoyloxymethylketone |
---|---|
Synonym | More Synonyms |
Description | Z-Asp-CH2-DCB is an irreversible broad spectrum caspase inhibitor. Z-Asp-CH2-DCB also inhibits proteases with caspase-like activity. Z-D-CH2-DCB blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in staphylococcal enterotoxin B (SEB)-stimulated peripheral blood mononuclear cells (PBMC), and reduces SEB-1-stimulated T-cell proliferation in a dose-dependent manner. Z-Asp-CH2-DCB prevents SU5416-induced septal cell apoptosis and emphysema development[1][2][3]. |
---|---|
Related Catalog | |
In Vitro | Z-Asp-CH2-DCB (10-100 μM) blocks the production of IL-1β, TNF-α, IL-6, and IFN-γ in SEB-stimulated (200 ng; 16 hours) PBMC in a dose-dependent manner. The production of the chemokines MCP-1, MIP-1α, and MIP-1β was also suppresses. The inhibitory effect of Z-Asp-CH2-DCB on TSST-1-activated PBMC is similar, reducing IL-1β, IL-6, TNF-α, IFN-γ, MCP-1, MIP-1α, and MIP-1β to 10, 36, 25, 10, 11, 25, and 30%, respectively, of levels in untreated cells[1]. Z-Asp-CH2-DCB (10-100 μM; 48 hours) inhibits T-cell proliferation in PBMC stimulated with 200 ng of SEB/ml [1]. Cell Viability Assay[1] Cell Line: Human peripheral blood mononuclear cells Concentration: 10, 50, 100 μM Incubation Time: 48 hours Result: Inhibited T-cell proliferation in PBMC stimulated with SEB. |
In Vivo | Z-Asp-CH2-DCB (1 mg; i.p.; every day for 3 weeks) prevents SU5416-induced septal cell apoptosis[1]. Animal Model: Male Sprague-Dawley rats (SU5416+ Z-Asp-CH2-DCB group)[1] Dosage: 1 mg Administration: Intraperitoneal injection; every day for 3 weeks Result: The caspase 3-like activity in SU5416-treated rat lungs is significantly higher, whereas lungs from rats treated with SU5416+Z-Asp-CH2-DCB showed no increase in apoptotic activity. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Boiling Point | 674.2±55.0 °C at 760 mmHg |
Molecular Formula | C20H17Cl2NO7 |
Molecular Weight | 454.258 |
Flash Point | 361.6±31.5 °C |
Exact Mass | 453.038208 |
PSA | 119.00000 |
LogP | 5.29 |
Vapour Pressure | 0.0±2.2 mmHg at 25°C |
Index of Refraction | 1.594 |
WGK Germany | 3 |
---|
pase-1 inhibitor v |
ice inhibitor vi |
(3S)-3-{[(Benzyloxy)carbonyl]amino}-5-[(2,6-dichlorobenzoyl)oxy]-4-oxopentanoic acid |
Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[(phenylmethoxy)carbonyl]amino]butyl ester |
pase-1 inhibitor iii |
z-d-ch2-dcb |
z-asp-ch2-dcb |
ice inhibitor v |